69559-56-4

Upstream product

• 551-93-9 2-aminoacetophenone 
• 76-02-8 trifluoroacetyl chloride 
• 121-44-8 triethylamine 

Downstream Products

• 6140-12-1 N-(2-acetylphenyl)-2,2-dichloroacetamide 
• 34790-24-4 4-methyl-1,2-dihydro-2-oxoquinazoline 
• 1591672-19-3 3-phenyl-5-(piperidin-1-yl)imidazo[1,5-c]quinazoline 
• 1591672-21-7 4-(3-phenylimidazo[1,5-c]quinazolin-5-yl)morpholine 
• 6141-14-6 2-chloro-4-methylquinazoline 
• 34790-24-4 4-methylquinazolin-2-ol 
• 1374855-80-7 (E)-3-(4-chlorophenyl)-N-(2-(4-cyclopropyl-4-hydroxypiperidin-1-yl)-4-methylquinazolin-6-yl)but-2-enamide 
• 1374855-79-4 (E)-3-(4-chlorophenyl)-N-(2-(4-cyclopropyl-4-hydroxypiperidin-1-yl)-4-methylquinazolin-6-yl)acrylamide 
• 1374856-81-1 5-[1-(4-methyl-6-nitro-quinazolin-2-yl)-piperidin-4-yl]-1,1-dioxo-1λ6-[1,2,5]thiadiazolidine-2-carboxylic acid benzyl ester 
• 1374855-78-3 (E)-N-(2-(4-cyclopropyl-4-hydroxypiperidin-1-yl)-4-methylquinazolin-6-yl)-3-(4-(trifluoromethoxy)phenyl)but-2-enamide 
• 1374855-77-2 (E)-N-(2-(4-cyclopropyl-4-hydroxypiperidin-1-yl)-4-methylquinazolin-6-yl)-3-(4-(trifluoromethoxy)phenyl)acrylamide 
• 1374856-31-1 (E)-N-(2-(4-(N,N-dimethylsulfamoylamino)piperidin-1-yl)-4-methylquinazolin-6-yl)-3-(4-(trifluoromethoxy)phenyl)acrylamide 
• 1374855-76-1 (E)-3-(4-chlorophenyl)-N-(2-(4-hydroxypiperidin-1-yl)-4-methylquinazolin-6-yl)but-2-enamide 
• 1374856-25-3 (E)-3-(4-chlorophenyl)-N-(2-(4-(2-hydroxyacetamido)piperidin-1-yl)-4-methylquinazolin-6-yl)acrylamide 

Relevant academic research and scientific papers

N-Bu4NI-catalyzed selective dual amination of sp3 C-H bonds: Oxidative domino synthesis of imidazo[1,5-c]quinazolines on a gram-scale

An n-Bu4NI catalyzed domino reaction that involves selective dual amination of sp3 C-H bonds has been developed. The protocol affords a facile and efficient approach to the synthesis of imidazo[1,5-c] quinazolines under mild conditions.

Design and optimization of quinazoline derivatives as melanin concentrating hormone receptor 1 (MCHR1) antagonists: Part 2

Melanin concentrating hormone receptor 1 (MCHR1) antagonists have potential for the treatment of obesity and several CNS disorders. In the preceding article, we have described a novel series of quinazolines as MCHR1 antagonists and demonstrated in vivo proof of principle with an early lead. Herein we describe the detailed SAR and SPR studies to identify an optimized lead candidate having good efficacy in a sub-chronic DIO model with a good cardiovascular safety window.

Quinazoline and benzimidazole MCH-1R antagonists

We have modified the previously reported 2-aminoquinoline 1 to provide two novel series of MCH-1R antagonists. Representative compounds from the quinazoline and benzimidazole series have been shown to be potent and selective, with promising in vitro eADME profiles.

A novel class of sodium/calcium exchanger inhibitor: Design, synthesis, and structure-activity relationships of 3,4-dihydro-2(1H)-quinazolinone derivatives

Design, synthesis, and structure-activity relationships of 3,4-dihydro-2(1H)-quinazolinone derivatives as inhibitors of the sodium/calcium (Na+/Ca2+) exchanger are discussed. These studies, based on a lead compound 9a, which was identified in our library, involved systematic modification of three regions and revealed that (1) the 3,4-dihydro-2(1H)- quinazolinone having a tertiary amino alkyl side chain at the 3-position is essential for activity, (2) a nonsubstituted phenyl ring is most suitable for high activity, and (3) introduction of a 4-substituted piperidine moiety enhanced the activity, in particular 4-benzylpiperidin-1-yl showed strong inhibitory activity. Based on these SAR studies, a structurally novel and highly potent inhibitor against the Na+/Ca2+ exchanger, 12g (SM-15811), was discovered. In particular, SM-15811 directly inhibited the Na+-dependent Ca2+ influx via the Na+/Ca 2+ exchanger in cardiomyocytes with a high potency. The activity was almost two orders more potent than the lead compound 9a and SM-15811 exerted a protective effect against myocardial ischemic reperfusion injury. These Na +/Ca2+ inhibitors could have a therapeutic potential for the treatment of ischemic reperfusion injury.

BICYCLIC COMPOUNDS AND THEIR THERAPEUTIC USE

Compounds of the formula (1) are useful as MCH mediator, and in the therapy of obesity.

Discovery of a novel potent Na+/Ca2+ exchanger inhibitor: Design, synthesis and structure-activity relationships of 3,4-dihydro-2(1H)-quinazolinone derivatives

Design, synthesis and structure-activity relationships for 3,4-dihydro-2(1H)-quinazolinone derivatives with the inhibitory activities of the Na+/Ca2+ exchanger are discussed. These studies based on lead compound 1a lead to the discovery of a structurally novel and highly potent inhibitor against the Na+/Ca2+ exchanger 4f (SM-15811), which directly inhibited the Na+-dependent Ca 2+ influx via the Na+/Ca2+ exchanger in cardiomyocytes with a high potency.

Piperidinylalkyl quinazoline compounds, composition and method of use

Novel quinazoline derivatives, comprising in the heterocyclic part of their quinazoline nucleus at least one carbonyl or thiocarbonyl group and a particularly substituted piperidinyl-alkyl side chain, said compounds being potent serotonin-antagonists.